Cargando…
Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer
Breast cancer is a leading cause of cancer-related death worldwide. Approximately 75% of breast cancer is hormone receptor-positive (HR(+)) and is managed with endocrine therapies. However, relapse or disease progression caused by primary or acquired endocrine resistance is frequent. Phosphatidylino...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199833/ https://www.ncbi.nlm.nih.gov/pubmed/25336989 http://dx.doi.org/10.2147/CMAR.S56802 |